je.st
news
4 Reasons To Keep An Eye On Top Biotech Celgene
2015-08-22 16:57:54| Biotech - Topix.net
While Celgene has pulled back with the market, growth prospects for the IBD Big Cap 20 biotech leader remain healthy. Boosted by its buyout of Receptos and investment in Juno Therapeutics, the maker of cancer therapy Revlimid projects revenue growth to more than double to $21 billion in 2020.
Tags: top
reasons
eye
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||